Tebentafusp-Tebn
Phase 2Small molecule
Tebentafusp-Tebn is one of 30 small molecule programs targeting Metastatic Uveal Melanoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
29 competitors in Uveal Melanoma
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Yervoy
Bristol-Myers SquibbPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Alkeran
AApotex Inc.
Approved
Signifor
RRECORDATI GROUP
Approved
Xalkori
PPrism Pharmaceuticals
Phase 3
KIMMTRAK
IImmunocore Ltd
Phase 3
Sutent
PfizerPhase 2
Mekinist
NovartisPhase 2
Mektovi
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tebentafusp-Tebn. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TThomas Jefferson University